IFF Stock Analysis: International Flavors | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 22.471m USD | 12M Return: 37% | US4595061015 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 136M
EPS Trend: 81.0%
Qual. Beats: 0
Rev. Trend: -80.3%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
International Flavors & Fragrances (IFF) is a global manufacturer of flavors, fragrances, and specialty ingredients, operating through four segments: Taste, Food Ingredients, Health & Biosciences, and Scent. The Taste segment produces savory, beverage, sweet, and dairy flavor systems, as well as spices and seasonings. The Food Ingredients segment supplies natural, artificial, and plant-based specialty ingredients, including antioxidants, antimicrobials, proteins, emulsifiers, and sweeteners. The Health & Biosciences segment provides enzymes, food cultures, probiotics, and ingredients for animal nutrition and grain processing. The Scent segment creates fragrance compounds and ingredients. The company was founded in 1909 and is headquartered in New York.
IFF operates as a business-to-business supplier within the specialty chemicals sector, selling ingredients and formulations to consumer goods manufacturers (such as food, beverage, personal care, and household product companies) rather than directly to end consumers. Its products are typically incorporated in small quantities into finished goods, making the flavors and fragrances industry highly dependent on R&D capabilities and long-standing customer relationships.
- IFF accelerates divestitures to reduce leverage from N&B deal
- Health & Biosciences margin recovery drives segment profitability
- Scent and Taste volumes weaken on softer global consumer demand
| Net Income: 290.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.01 > 1.0 |
| NWC/Revenue: 46.88% < 20% (prev 24.29%; Δ 22.60% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.16b > Net Income 290.0m |
| Net Debt (5.67b) to EBITDA (1.49b): 3.82 < 3 |
| Current Ratio: 2.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (257.0m) vs 12m ago 0.0% < -2% |
| Gross Margin: 37.52% > 18% (prev 36.25%; Δ 1.28% > 0.5%) |
| Asset Turnover: 38.92% > 50% (prev 43.27%; Δ -4.35% > 0%) |
| Interest Coverage Ratio: 2.88 > 6 (EBIT TTM 538.0m / Interest Expense TTM 187.0m) |
| A: 0.19 (Total Current Assets 9.09b - Total Current Liabilities 4.41b) / Total Assets 25.2b |
| B: -0.14 (Retained Earnings -3.40b / Total Assets 25.2b) |
| C: 0.02 (EBIT TTM 538.0m / Avg Total Assets 25.6b) |
| D: 1.25 (Book Value of Equity 14.0b / Total Liabilities 11.1b) |
| Altman-Z'' = 2.24 = BBB |
| DSRI: 0.78 (Receivables 1.42b/2.06b, Revenue 9.98b/11.3b) |
| GMI: 0.97 (GM 36.25% / 37.52%) |
| AQI: 0.86 (AQ_t 0.51 / AQ_t-1 0.60) |
| SGI: 0.88 (Revenue 9.98b / 11.3b) |
| TATA: -0.03 (NI 290.0m - CFO 1.16b) / TA 25.2b) |
| Beneish M = -3.41 (Cap -4..+1) = AA |
As of August 08, 2026, the stock is trading at USD 85.89 with a total of 1,033,766 shares traded. Over the past week, the price has changed by +8.42%, over one month by +4.96%, over three months by +10.33% and over the past year by +36.96%.
Current recommended Stop Loss: 81.30 (which is 5.3% or 1.6 ATR below the current price).
International Flavors has received a consensus analysts rating of 4.32. Therefore, it is recommended to buy IFF.
- StrongBuy: 10
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 91.5 | 6.6% |
P/E Trailing = 25.0912
P/E Forward = 17.9856
P/S = 2.4577
P/B = 1.4626
P/EG = 0.9022
Revenue TTM = 9.98b USD
EBIT TTM = 538.0m USD
EBITDA TTM = 1.49b USD
Long Term Debt = 4.74b USD (from longTermDebt, last quarter)
Short Term Debt = 964.0m USD (from shortTermDebt, last quarter)
Debt = 6.24b USD (from shortLongTermDebtTotal, last quarter) + Leases 544.0m
Net Debt = 5.67b USD (calculated: Debt 6.24b - CCE 569.0m)
Enterprise Value = 28.1b USD (22.5b + Debt 6.24b - CCE 569.0m)
Interest Coverage Ratio = 2.88 (Ebit TTM 538.0m / Interest Expense TTM 187.0m)
EV/FCF = 52.31x (Enterprise Value 28.1b / FCF TTM 538.0m)
FCF Yield = 1.91% (FCF TTM 538.0m / Enterprise Value 28.1b)
FCF Margin = 5.39% (FCF TTM 538.0m / Revenue TTM 9.98b)
Net Margin = 2.91% (Net Income TTM 290.0m / Revenue TTM 9.98b)
Gross Margin = 37.52% ((Revenue TTM 9.98b - Cost of Revenue TTM 6.23b) / Revenue TTM)
Gross Margin QoQ = 43.65% (prev 37.14%)
Tobins Q-Ratio = 1.12 (Enterprise Value 28.1b / Total Assets 25.2b)
Interest Expense / Debt = 3.00% (Interest Expense 187.0m / Debt 6.24b)
Taxrate = 21.65% (76.0m / 351.0m)
NOPAT = 421.5m (EBIT 538.0m * (1 - 21.65%))
Current Ratio = 2.06 (Total Current Assets 9.09b / Total Current Liabilities 4.41b)
Debt / Equity = 0.45 (Debt 6.24b / totalStockholderEquity, last quarter 14.0b)
Debt / EBITDA = 3.82 (Net Debt 5.67b / EBITDA 1.49b)
Debt / FCF = 10.55 (Net Debt 5.67b / FCF TTM 538.0m)
Total Stockholder Equity = 14.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.13% (Net Income 290.0m / Total Assets 25.2b)
RoE = 2.05% (Net Income TTM 290.0m / Total Stockholder Equity 14.1b)
RoCE = 2.85% (EBIT 538.0m / Capital Employed (Equity 14.1b + L.T.Debt 4.74b))
RoIC = 1.99% (NOPAT 421.5m / Invested Capital 21.2b)
WACC = 6.94% (E(22.5b)/V(28.7b) * Re(8.21%) + D(6.24b)/V(28.7b) * Rd(3.00%) * (1-Tc(0.22)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.07 | Cagr: 0.17%
[DCF] Terminal Value 74.89% ; FCFF base≈546.8m ; Y1≈531.0m ; Y5≈526.2m
[DCF] Fair Price = 10.07 (EV 8.24b - Net Debt 5.67b = Equity 2.57b / Shares 255.1m; r=8.35% [WACC [floored]]; 5y FCF grow -3.93% → 2.50% )
EPS Correlation: 81.01 | EPS CAGR: 7.31% | SUE: 0.19 | # QB: 0
Revenue Correlation: -80.26 | Revenue CAGR: -3.66% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-09-30): EPS=1.15 | Chg30d=+0.17% | Revisions=+17% | Analysts=11
EPS current Year (2026-12-31): EPS=4.49 | Chg30d=-0.10% | Revisions=-22% | GrowthEPS=+7.0% | GrowthRev=-1.4%
EPS next Year (2027-12-31): EPS=4.80 | Chg30d=-0.35% | Revisions=-12% | GrowthEPS=+6.8% | GrowthRev=+2.9%
[Analyst] Revisions Ratio: -12% (up=6, down=8)